Vitamin D deficiency is highly prevalent among dialysis patients, and has been associated with cardiovascular risk factors such as increased aortic pulse wave velocity, blood pressure, inflammation, and brain natriuretic peptide. This study will evaluate the effect of 26 weeks of vitamin D3 supplementation in patients with end stage renal disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
64
3 tablets of 1000 IU daily for 26 weeks
3 tablets of 1000 IU daily for 26 weeks
Departments of Medical Research and Medicine, Holstebro Hospital
Holstebro, Holstebro, Denmark
Plasma concentration of NT-proBNP
Time frame: 26 weeks
Plasma concentration of ionized calcium
Time frame: 4 weeks
Plasma concentration of phosphate
Time frame: 4 weeks
Plasma concentration of PTH
Time frame: 4 weeks
Plasma concentration of 25-hydroxycholecalciferol
Time frame: 4 weeks
24-hour blood pressure
Time frame: 26 weeks
Plasma renin concentration
Time frame: 26 weeks
Plasma concentration of angiotensin II
Time frame: 26 weeks
Plasma concentration of aldosterone
Time frame: 26 weeks
Arterial stiffness
Time frame: 26 weeks
Serum concentration of FGF-23
Time frame: 26 weeks
Plasma concentration of AVP
Time frame: 26 weeks
Plasma concentration of ANP
Time frame: 26 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Plasma concentration of TNF alpha
Time frame: 26 weeks
Heart Function
Time frame: 26 weeks